TAK-243 is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TAK-243’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAK-243 overview
TAK-243 (MLN-7243) is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), chronic monomyelocytic leukemia, myelodysplastic syndrome and lymphoma. The drug candidate is administered through intravenous route. The drug candidate is a small molecule and an inhibitor of Ubiquitin-Activating Enzyme (UAE). It was under development for the treatment of advanced solid tumors and multiple myeloma.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Co Ltd is developing drugs for the treatment of solid tumor and multiple myeloma. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of TAK-243’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
